Cellectar BioSciences, Inc. (CLRB)
| Market Cap | 17.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.30M |
| Shares Out | 6.11M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,076 |
| Open | 1.89 |
| Previous Close | 1.87 |
| Day's Range | 1.81 - 1.91 |
| 52-Week Range | 1.75 - 7.9 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 12.85 (+594.6%) |
| Earnings Date | Nov 14, 2022 |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is 12.85, which is an increase of 594.59% from the latest price.
News
Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...
Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the ...
Preclinical data demonstrate ability to deliver targeted alpha-emitting isotopes to malignant cells and therapeutic efficacy Preclinical data demonstrate ability to deliver targeted alpha-emitting isoto...
Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute
Secures license to the patents at issue in the lawsuit Secures license to the patents at issue in the lawsuit
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...
Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximat...
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...
Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 M...
FLORHAM PARK, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...
Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors
FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of t...
Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in ...
Initial data show ORR of 50% in Quad-Class Refractory Multiple Myeloma Patients Who Have Failed anti-BCMA Immunotherapy with Median of Nine Lines of Prior Therapy Initial data show ORR of 50% in Quad-Cl...
Cellectar Reports Financial Results for Second Quarter 2022
FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...
Cellectar Announces Stock Consolidation
FLORHAM PARK, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of ta...
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update
FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializati...
Cellectar Biosciences Announces Key Commercial Team Appointments
Matthew Hagan Appointed Vice President, Marketing and Strategic Alliances
Here's Why Cellectar Biosciences Shares Are Rising
Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earn...
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update
FLORHAM PARK, N.J., March 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializa...
Cellectar to Participate at Upcoming Banking Conferences
FLORHAM PARK, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercializ...
Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...
Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting a...
Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Ex...
FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...
Cellectar's Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors
FLORHAM PARK, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializat...
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted dru...
Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer
Successful track record of developing and advancing oncology clinical programs through regulatory approval Successful track record of developing and advancing oncology clinical programs through regulato...
Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer
Cellectar Biosciences Inc (NASDAQ: CLRB) has completed part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed o...
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for t...
Cellectar Receives $2M NIH Grant For Rare Lymphoma Study
Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the Na...
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's ...
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for th...